Eligible participants must be healthy adults without any underlying conditions, aged between 18-59, with no history of contracting SARS, MERS or COVID-19, and who have not received any other COVID-19 vaccine.
Phase I of the clinical trials is scheduled to begin on August 15, when the ARCT-154 vaccine will be administered to 100 volunteers at the Hanoi Medical University.
Phase II will be conducted on 300 volunteers and Phase III will involve 20,600 volunteers.
In addition to the Hanoi Medical University, the Pasteur Institute in Ho Chi Minh City and the Vietnam Military Medical University will also take part in the clinical trials.
ARCT-154 is a COVID-19 vaccine developed by Arcturus Therapeutics using self-amplifying RNA technology, which has been improved to be effective against the Delta variant.
VinBioCare is planning to build a plant to manufacture this vaccine at the Hoa Lac High-Tech Park on the outskirts of Hanoi.
